Measles is a highly contagious disease which can result in severe complications in some patients. Healthcare workers have a higher risk of getting measles than the general population because of their increased risk of exposure from patients with measles attending hospitals. Having had measles in the past or at least one dose of the measles, mumps and rubella (MMR) vaccine provides protection (immunity) against measles. UK government guidelines therefore recommend that healthcare workers and non-clinical staff with direct patient contact are fully vaccinated or have other evidence of immunity. Yet, evidence from recent measles outbreaks suggests that some healthcare workers are not immune or do not know if they are immune, with implications for containment efforts, cost and transmission. The purpose of this study is to identify barriers and facilitators to uptake of the MMR vaccine among healthcare workers at King's College Hospital NHS Foundation Trust (KCH). KCH healthcare workers will be eligible to take part in the study if they are aged 18 and over and have direct contact with patients. In addition, the research will focus on four subgroups of healthcare workers at KCH: those who are not immune, those who have not completed the full vaccination schedule, those who don't know their immunity status, those received the vaccine only after joining KCH. The latter may provide insights into facilitators to vaccine uptake. Measles immunity forms part of the occupational health screening at KCH. A series of semi structured interviews lasting approximately 1 hour will explore participants' experiences of the occupational health vaccine screening process and measles vaccine campaigns at KCH; why they are unvaccinated/not fully vaccinated/do not know if they are immune/decided to be vaccinated after joining KCH; and what measures or interventions may help healthcare workers when deciding whether to get the MMR vaccine.

开始日期2024-07-01

申办/合作机构

King's College London

[+1]

PACTR202405741158761 / Suspended临床3期

A Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study to Evaluate the Immunogenicity and Safety of Shanghai Institute of Biological Products Co., Ltd.’s Measles, Mumps and Rubella (MMR) Vaccine Compared to a Licensed and WHO Prequalified GSK MMR Vaccine in Healthy African Children, 9- 11 Months of Age.

开始日期2024-06-17

申办/合作机构

上海生物制品研究所有限责任公司

NCT06397768 / Recruiting临床3期

Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL)

This study is a Phase III, randomized, single-blind, placebo-controlled, multi-center study to be conducted in healthy infants and toddlers aged 6 months + 2 weeks for Cohort 1 and 12 months ± 2 weeks for Cohort 2. The primary objective of the study will be to assess non-inferiority of the respiratory syncytial virus toddler and infant (RSVt) vaccine antibody response when administered concomitantly with routine pediatric vaccines at 6 months of age (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine [Vaxelis® or Pentacel® and Recombivax HB®] Prevnar 20®, and RotaTeq®), and 12 months of age (M-M-R II, VARIVAX, and Prevnar 20 or per local country recommendations) compared to when administered non-concomitantly.

开始日期2024-05-13

申办/合作机构

Sanofi Pasteur

100 项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的临床结果

登录后查看更多信息

100 项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的转化医学

登录后查看更多信息

100 项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的专利（医药）

登录后查看更多信息

363

项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的文献（医药）

2024-02-01·EClinicalMedicine

Immunogenicity and reactogenicity following MMR vaccination in 5–7-month-old infants: a double-blind placebo-controlled randomized clinical trial in 6540 Danish infants

Article

作者: Stensballe, Lone Graff ; Malon, Michelle ; Buus, Søren ; Jensen, Andreas ; Zimakoff, Anne Cathrine ; Johansen, Marie Ryberg ; Kirkby, Nikolai Søren ; Sørensen, Jesper Kiehn ; Svensson, Jannet ; Simões, Eric A F ; Vittrup, Dorthe Maria ; Charabi, Salma

Background:

Measles is a highly contagious viral disease. Vaccinated mothers transfer fewer antibodies during pregnancy, resulting in shortened infant immunity. Earlier primary vaccination might avert the gap in protection.

Methods:

Healthy 5-7-month-old Danish infants were assigned in a 1:1 ratio to M-M-RVaxPro or placebo (solvent) in a double-blind, randomized trial between April 15, 2019 and November 1, 2021 (ClinicalTrials.govNCT03780179, EudraCT 2016-001901-18). Eligibility criteria were birth weight >1000 g and gestational age ≥32 weeks.Immunogenicity was measured by plaque reduction neutralization test (PRNT) and IgG ELISA before intervention, four weeks after intervention and routine MMR. Reactogenicity data were collected for six weeks and measured by hazard ratios (HR).

Findings:

647 and 6540 infants participated in the immunogenicity and reactogenicity study, respectively; 87% and 99% completed follow-up. After early MMR, seroprotection rates (SPRs) were 47% (13%) in measles PRNT; 28% (2%), 57% (8%) in mumps and rubella IgG (placebo). For measles PRNT, geometric mean ratio was 4.3 (95% CI: 3.4-5.3) between randomization groups after intervention and 1.5 (95% CI: 1.3-1.9) after routine MMR.Reactogenicity was independent of randomization (HR, 1.0; 95% CI: 0.9-1.1). Severe adverse events occurred in 25 infants (HR, 1.8; 95% CI: 0.8-4.0); none deemed vaccine related.

Interpretation:

Early MMR elicited low SPRs but did not negatively impact short-term responses to a subsequent MMR. MMR at 5-7 months was safe and not associated with higher rates of reactogenicity than placebo.

Funding:

Innovation Fund Denmark.

2024-03-11·Human vaccines & immunotherapeutics3区 · 医学

Prevention of measles, mumps and rubella: 40 years of global experience with M-M-R _II

3区 · 医学

Article

作者: Fergie, Jaime ; Marshall, Gary S. ; Schmidt, Elvira ; Kuter, Barbara J. ; Pawaskar, Manjiri

Measles, mumps, and rubella are highly contagious diseases that caused significant global mortality and morbidity in the pre-vaccine era. Since its first approval in the United States over 40 years ago, M-M-R_II has been used in >75 countries for prevention of these diseases. The vaccine has been part of immunization programs that have achieved dramatic global reductions in case numbers and mortality rates, as well as the elimination of measles and rubella in several countries and regions. This report summarizes over four decades of global safety, immunogenicity, efficacy, and effectiveness data for the vaccine. We include studies on the use of M-M-R_II in different age groups, concomitant use with other routine childhood vaccines, administration via different routes, persistence of immunity, and vaccine effectiveness during outbreaks of measles and mumps. We conclude that M-M-R_II is well tolerated and has shown consistently high performance during routine use in multiple countries, in randomized controlled trials with diverse designs, and in outbreak settings, including use as measles postexposure prophylaxis. Physicians, parents, and the public can continue to have a high degree of confidence in the use of M-M-R_II as a vital part of global public health programs.

2024-01-01·Journal of public health management and practice : JPHMP

Achieving Equity in Childhood Vaccination: A Mixed-Methods Study of Immunization Programs, Policies, and Coverage in 3 US States

Article

作者: Mokdad, Ali H ; Brumbaugh, Kaitlin Quirk ; Casas, Francisco Rios ; Ornelas, India J

Objective::

In this study, we sought to understand patterns of childhood vaccinations in the United States across socioeconomic and racial/ethnic groups over a 12-year period to identify interventions that improve immunization equity and inform public health practice.

Design::

We conducted an explanatory, sequential, mixed-methods study. US state- and county-level immunization data were analyzed to understand trends in immunization coverage among racial/ethnic groups. Qualitative interviews with public health and community leaders were used to explain trends, gain insight into routine childhood immunization interventions, and understand local contexts and data limitations.

Participants and Setting::

Secondary data were used from the National Immunization Survey—Child (NIS) public use data sets (2007 and 2019). Eligible participants for qualitative interviews were routine childhood immunization stakeholders from selected counties in North Carolina, Washington, and Arizona.

Main Outcome Measure::

Our integrated findings report trends and probability of children aged 19 months to 3 years being fully vaccinated (measles-mumps-rubella [MMR], diphtheria and tetanus toxoids and acellular pertussis [DTaP], hepatitis B [Hep B]), interventions, and recommendations to improve routine childhood immunization coverage and equity.

Results::

Vaccination coverage remained high and relatively stable between 2007 and 2019; however, there were differences across racial/ethnic groups. Public health leaders identified key interventions that effectively improved vaccine equity and coverage, including data quality improvement, tailored interventions for specific populations, multisector partnerships, addressing common barriers, and data limitations. Participants also identified the critical role of state policies, public health funding, and community vaccine norms.

Conclusions::

Variability persists in vaccination coverage and equity across states, race/ethnicity, and socioeconomic status despite decades of interventions. Vaccine stakeholders should use our findings to improve coverage and reduce disparities. Equitable improvements can be realized through policy change, data tracking/infrastructure improvements, and tailored interventions. Furthermore, local partners are critical in improving vaccine coverage and equitable interventions to disrupt disparities that long hold true for vaccine-preventable diseases.

项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的新闻（医药）

2024-04-05

·Pharmaceutical Technology

England’s MMR vaccinations up 23% following NHS initiative

Vaccinations were up four fold in those aged five to 25 years old. Image credit: Shutterstock/didesign021. England’s NHS is calling its recent campaign to boost vaccination rates a success amidst a surge in measles, mumps , and rubella (MMR) cases. Latest data released by the health service shows that there were 23% more vaccinations in the first quarter of 2024 compared to the same time last year. A total of 360,964 jabs were delivered between January and March this year, compared to 293,847 in 2023. The biggest jump was seen in those aged five to 25 years old, with vaccinations up four-fold in that group between 2024 and 2023. In January, the UK Health Security Agency (UKHSA) declared a national incident following a surge in measles outbreaks across Britain. The highly contagious measles virus can cause serious illness and, in some cases, even death, in children and adults. It is also dangerous if caught during pregnancy, potentially resulting in stillbirth, miscarriage, and low birth weight. In the same month, the NHS started contacting millions of patients and carers in England to book their children in for a catch-up vaccine with a GP. The campaign also targeted those in the 11 to 25 year-age group in areas with low vaccine uptake rates such as London and the West Midlands. See Also: Touchlight joins forces with University of Liverpool for NSCLC vaccine Zoetis gets grant for recombinant viral vectors for multivalent pathogen protection in vaccines At the time, the NHS said its figures indicated that more than 3.4 million children under 16 years of age were unprotected against the three infectious diseases. There have been 934 confirmed cases of measles in England since the beginning of October last year, according to data from the UKSHA. The West Midlands accounted for around half of the cases seen since January. UKSHA head of immunisation Dr Mary Ramsay said: “The big increase in people, especially children, getting their MMR vaccine following our recent marketing campaign on missed immunisations is fantastic to see.” The NHS uses MSD’s M-M-RVaxPro and GSK ’s Priorix for MMR vaccines. The shots were approved for use in the UK in 1997 and 2006, respectively. They are recommended for all babies and young children, with adults able to receive one if unvaccinated. Two doses of the vaccines are required, resulting in lifelong protection with high efficacy against the three viruses which are easily spread between unvaccinated people. The World Health Organization (WHO) has said 95% vaccine coverage would eliminate measles in a population completely. The US has also seen a surge in measles cases , with the Centers for Disease Control and Prevention (CDC) reporting 97 cases in 2024 so far. Over half of the patients diagnosed with the virus were hospitalised. The CDC issued a health alert urging travellers, especially children, to get vaccinated. A statement from the American Medical Association echoed the call for vaccinations. The US also uses MSD’s M-M-R II and GSK’s Priorix.

疫苗上市批准

2024-03-21

·GlobeNewswire-Health Care

Rate of national measles cases highlights importance of vaccination

JEFFERSON CITY, Mo., March 21, 2024 (GLOBE NEWSWIRE) -- As vaccine uptake continues to decrease, measles cases or outbreaks have emerged in several states, including Missouri earlier this year. Nationally, the total number of measles cases has already reached the level that occurred during the entire year of 2023. With cases reported across the country, the Missouri Department of Health & Senior Services (DHSS) recommends parents and guardians check their child’s vaccination records to make sure they have received the measles, mumps and rubella (MMR) vaccine. This vaccine has been used in the United States since the 1970s and is a safe and effective way to protect children from measles. To be fully immunized, children are recommended to receive two doses of the MMR vaccine, with the first dose between ages 12-15 months and the second dose between ages 4-6 years old. Infants as young as 6 months can receive the first dose if traveling to areas where the measles infection rate is high. Families should consult their health care provider to discuss appropriate vaccine options for their children. Herd immunity, achieved through a measles vaccination rate of 95% or more, is crucial for preventing disease outbreaks in the community and protecting vulnerable populations who cannot receive vaccines. “Achieving this level of vaccination creates a barrier that limits the spread of infectious disease within a community, safeguarding those who are unable to be vaccinated due to their age or compromised immune systems,” said Dr. George Turabelidze, state epidemiologist with DHSS. Statewide, the MMR vaccination rate among kindergarteners has dropped steadily from 95.4% in the 2016-2017 school year to 90.5% at the start of the 2023-2024 school year, according to preliminary data reported by Missouri school districts. Religious (non-medical) exemptions have simultaneously increased from 1.9% to 3.5%. The measles vaccine, given as part of the MMR (measles, mumps and rubella) vaccine, is extremely effective, giving those vaccinated with just one dose 93% protection against measles infection. Both doses of the vaccine provide individuals with a 97% protection rate throughout their lifetime. Measles is a highly contagious and serious disease, especially serious for children under age five and those who are immunocompromised. Common symptoms include a rash that starts as flat red spots on the head and spreads to other parts of the body, high fever, cough, runny nose, red and watery eyes, and tiny white spots inside the mouth. But in some instances, individuals with measles will develop brain infection, which can lead to brain damage, and for some, the disease is fatal even with the best care. The virus spreads through coughing and sneezing and can live for up to two hours in an airspace after an infected person leaves an area. A person can spread measles without knowing they are infected. If not treated, complications can grow in severity. Most health insurance plans cover vaccines, but individuals should check with their insurance provider to verify coverage. For those without insurance, the Vaccines for Children Program, funded by the Centers for Disease Control and Prevention (CDC), provides free vaccines to children who qualify. Additionally, most local public health agencies throughout the state of Missouri offer vaccinations at affordable rates. To find a local public health agency near you and schedule an appointment, visit the Local Public Health Agency Directory. Mission of the Missouri Department of Health and Senior Services (DHSS): To promote health and safety through prevention, collaboration, education, innovation and response. MEDIA CONTACT:Lisa Cox (573-751-6062)Missouri Department of Health and Senior ServicesMedia Inquiry Form

疫苗

2024-02-01

·医药魔方

默沙东2023年财报：K药250亿美元登顶“药王”宝座，HPV疫苗近90亿美元

2月1日，默沙东公布2023年业绩，全年营收601.15亿美元，同比增长1%，扣除新冠口服药Lagevrio（莫诺拉韦）影响后，同比增长9%。默沙东制药业务收入535.83亿美元，同比增长3%，其中，中国区收入67.1亿美元，占据默沙东全球市场12.5%的份额，同比增长32%。王牌品种Keytruda（帕博利珠单抗）迎来其历史性高光时刻，全年营收250.11亿美元，同比增长19%，荣登2023年“药王”宝座。主要得益于在全球早期癌症患者群体（包括TNBC和RCC）中的使用，以及在全球转移性癌症患者中持续的强劲需求。九价HPV疫苗Gardasil/Gardasil 9销售额达88.86亿美元（+29%）。这两款产品占据默沙东总收入的56.4%，也成就了默沙东在肿瘤和疫苗领域的行业领导者地位。肿瘤领域产品Welireg（HIF-2α抑制剂）和Reblozyl（罗特西普），抗巨细胞病毒感染药物Prevymis（来特莫韦），以及15价肺炎球菌疫苗Vaxneuvance（V114）的销售额均呈现双位数及以上增长，带来了可观的增量收入。2023年默沙东主要产品销售额（亿美元）Keytruda无疑是默沙东的荣耀，自上市以来在与O药的缠斗中，已经将对手远远甩在身后。与此同时，这款超级重磅药物也面临2028年专利悬崖危机。不过在今年的JPM大会上，默沙东首席执行官Rob Davis向外界传达了乐观的信号，他表示，“现阶段讨论的焦点无疑是Keytruda和2028，不过我们越来越不再关注2028年，这只是一个年份而已。”Rob Davis拥有如此底气也不足为奇，毕竟默沙东已经针对这一即将面临的挑战未雨绸缪，做出了充分的应对措施。2023年，默沙东针对Keytruda新开了多项联合治疗III期临床研究，其中包括与肿瘤mRNA疫苗V940（mRNA-4157）联合治疗非小细胞肺癌（NSCLC）的两项研究，以及与TROP2 ADC新药MK-2870（从科伦博泰引进）联合一线治疗NSCLC的关键III期研究。除了继续挖掘Keytruda与其他疗法联合的治疗潜力，默沙东还计划通过增补肿瘤产品管线进一步丰富产品群来应对肿瘤业务可能面临的收入下滑情况。LSD1抑制剂Bomedemstat、BTK抑制剂Nemtabrutinib以及CYP11A1抑制剂MK-5684均被推向了III期临床。另外，去年10月，默沙东还以高达220亿美元的总金额引进了第一三共3款ADC新药 patritumab deruxtecan（HER3-DXd）、ifinatamab deruxtecan（I-DXd）和raludotatug deruxtecan（R-DXd），其中patritumab deruxtecan上市申请已于2023年12月获得FDA优先审评，适应症为三线治疗EGFR突变NSCLC。今年，受益于ADC候选药物以及癌症疫苗，默沙东将其肿瘤学组合下一个十年预估值提升到了200亿美元以上。疫苗领域，宫颈癌疫苗Gardasil/ Gardasil 9贡献了最核心的份额，同比增长29%至88.86亿美元，这主要仍得益于中国市场的强劲需求。用于预防麻疹、腮腺炎或水痘的ProQuad/M-M-R II/Varivax系列疫苗的销售额稳健增长达到23.68亿美元，另一种针对婴幼儿轮状病毒感染疫苗RotaTeq的销售额为7.69亿美元。默沙东和辉瑞在肺炎球菌疫苗赛道上开展了一场持久拉锯战。2023年，23价肺炎球菌疫苗Pneumovax 23销售额持续大幅下滑仅为4.12亿美元，跌幅达32%，也是默沙东财报中销售额下跌最严重的产品之一。而辉瑞Prevnar系列产品2023年卖出了64.4亿美元的好成绩。不过，默沙东在肺炎球菌疫苗赛道仍然有赶超辉瑞之势，15价肺炎球菌疫苗Vaxneuvance（V114）已于2021年7月获批上市，2022年8月将适用人群覆盖至6周龄以上儿童，2023年的销售额是2022年的近4倍，已达到6.65亿美元；用于成人的21价肺炎球菌疫苗V116对标Prevnar 20，已于2023年12月向FDA递交了上市申请并被纳入优先审评，如果获得上市批准，V116将成为首个专为成人设计的肺炎球菌结合疫苗。此外，默沙东布局在心血管/代谢、神经和免疫疾病领域都有产品布局，每一个细分赛道中都有新生代产品即将进入收获期或进入后期开发阶段，有望进一步补强现有产品群。在Adempas（2.55亿美元，+7%）的基础上，肺动脉高压新药Sotatercept蓄势待发，其生物制品许可申请（BLA）已获FDA授予优先审评资格，PDUFA日期定为2024年3月26日。代谢领域两款治疗2型糖尿病的产品Januvia与Janumet市场份额进一步萎缩。不过，其在研GLP-1R/GCGR双靶点激动剂efinopegdutide用于治疗非酒精性脂肪性肝炎 (NASH)的IIa期临床研究已于去年6月公布了积极结果。刚过去的JPM大会上，Robert Davis表示正在寻求具有减肥以外益处的GLP-1靶向疗法，因为非减肥适应症的开发更容易获得报销。心血管领域，口服PCSK9抑制剂MK-0616被寄予厚望，去年8月，默沙东新开了MK-0616治疗成人高胆固醇血症的大型III期CORALreef研究，该项目将在三项全球性研究中招募约17000名受试者，研究结果颇受期待。2023年，默沙东研发投入高达305.31亿美元，相当于将2023年收入的一半用于研发，其中仅收购与剥离造成的相关成本高达81.9亿美元。而其2022年的研发投入仅为135.48亿美元。仅在2023年，默沙东共启动了20多个III期研究项目。其中包括8款新的资产首次于2023年进入III期阶段。足以看出其在新药研发过程中重金投入的魄力。默沙东表示，今年计划开展更多临床试验。与此同时，Rob Davis表示，该公司正在寻找更多的中型交易。默沙东也对2024年业绩做了展望，预计全年收入将达到626-642亿美元。推荐阅读强生2023年财报出炉！乌司奴单抗超108亿美元，达雷妥尤单抗逼近百亿美元赛诺菲2023年财报：度普利尤单抗117亿美元，已在中美欧申报COPD适应症罗氏2023年财报：眼科双抗上市两年突破26亿美元，中国区收入60亿美元诺和诺德2023年财报：司美格鲁肽大卖212亿美元，Wegovy增长407%诺华2023年财报：Entresto销售额破60亿美元，中国区业绩增长17%GSK RSV疫苗销售额破十亿美元，继续领先辉瑞辉瑞2023年财报：营收585亿美元，RSV疫苗收入8.9亿美元翻倍增长！Enhertu 2023年全球销售25亿美元Copyright © 2024 PHARMCUBE. All Rights Reserved.欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。

疫苗财报临床3期信使RNA优先审批

100 项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07BD52	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
麻疹	美国	Merck & Co., Inc.	1971-04-22
腮腺炎	美国	Merck & Co., Inc.	1971-04-22
风疹	美国	Merck & Co., Inc.	1971-04-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00148941 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	4,209	SB213503 lot 1+M-M-R II (SB213503 Lot 1 + M-M-R Group)	範齋鹽鏇選願衊鹹憲淵(壓製窪糧襯餘醖襯願餘) = 艱構壓餘鏇膚顧壓糧觸窪廠糧窪廠製願簾壓艱 (鏇齋壓壓範餘齋遞願網, 餘壓餘網壓繭衊選網憲 ~ 範鬱壓衊齋製夢製簾壓) 更多	-	2020-02-05
				SB213503 lot 2+M-M-R II (SB213503 Lot 2 + M-M-R Group)	範齋鹽鏇選願衊鹹憲淵(壓製窪糧襯餘醖襯願餘) = 蓋遞膚鬱鏇夢選衊構艱窪廠糧窪廠製願簾壓艱 (鏇齋壓壓範餘齋遞願網, 願築簾網繭淵鏇齋鏇願 ~ 獵衊鏇鑰範鏇築艱糧築) 更多
NCT03239873 (V210-A03, CTgov)	临床3期	水痘	600	VARIVAX PE34+M-M-R II (VARIVAX PE34 + M-M-R II)	鏇鏇簾鹹襯顧鏇鏇襯憲(窪壓獵鑰積繭淵醖顧襯) = 構襯選襯鑰觸淵築膚窪觸願顧簾顧齋遞衊製鏇 (願鬱憲蓋艱顧鑰膚艱構, 積範蓋糧觸衊鏇衊淵齋 ~ 築鏇廠遞衊壓鹽觸範願) 更多	-	2019-08-26
				M-M-R® II vaccine (VARIVAX (2016 CP) + M-M-R II)	鏇鏇簾鹹襯顧鏇鏇襯憲(窪壓獵鑰積繭淵醖顧襯) = 獵顧衊餘願憲襯蓋鬱夢觸願顧簾顧齋遞衊製鏇 (願鬱憲蓋艱顧鑰膚艱構, 鑰襯鑰艱選繭積鑰鬱餘 ~ 齋積醖蓋鹹簾簾鏇艱鑰) 更多
NCT02062502 (V210-063, CTgov)	临床3期	水痘	611	VARIVAX™ 2007 process+M-M-R II™	餘醖餘簾鬱蓋鏇糧窪糧(觸選觸艱網積醖遞鏇蓋) = 築壓範鹽簾遞壓艱夢夢蓋醖製夢淵鏇構廠廠夢 (夢窪遞壓糧範鏇醖範醖, 繭鹽餘衊淵網窪繭願簾 ~ 簾構憲範築衊繭構製艱) 更多	-	2016-03-01
NCT01000311 (CTgov)	临床3期	脑膜炎球菌感染	529	PCV+HBV+MenACWY-CRM+MMR (MenACWY-CRM + Routine Vaccines)	範構構網夢製鏇憲願顧(鹹鏇壓鏇積顧獵齋膚鬱) = 壓蓋鹹淵範窪獵窪淵糧選鬱構繭鏇構鹹夢淵積 (遞積觸簾鹽淵鬱構鬱憲, 構蓋膚糧獵鑰網遞構憲 ~ 鑰構齋蓋鏇衊鬱齋鏇醖) 更多	-	2014-03-26
				PCV+HBV+MMR (Routine Vaccines)	範構構網夢製鏇憲願顧(鹹鏇壓鏇積顧獵齋膚鬱) = 壓鬱鑰壓夢醖醖範糧餘選鬱構繭鏇構鹹夢淵積 (遞積觸簾鹽淵鬱構鬱憲, 齋鹽範夢餘觸醖鹽積構 ~ 壓襯觸膚餘構鏇蓋窪壓) 更多
NCT00871117 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	478	Merck+GSK Biologicals'Kinrix®+Company's MMRII (Kinrix + M-M-R II + Varivax)	壓鏇餘憲鏇鑰窪築廠遞(襯窪鏇醖遞餘構築築築) = 鹽糧齋憲積餘窪遞繭壓積糧鏇鏇壓夢憲壓齋艱 (鏇簾鬱齋繭齋艱鑰襯網, 繭膚繭糧願窪壓顧範蓋 ~ 齋鑰夢選醖膚選網齋遞) 更多	-	2011-02-10
				Merck+GSK Biologicals'Kinrix®+Company's MMRII (Kinrix + M-M-R II -> Varivax)	壓鏇餘憲鏇鑰窪築廠遞(襯窪鏇醖遞餘構築築築) = 網鹹築鑰鹹鹹選鹽鬱窪積糧鏇鏇壓夢憲壓齋艱 (鏇簾鬱齋繭齋艱鑰襯網, 繭簾壓壓糧鏇觸鹽鬱鹹 ~ 廠壓窪夢鹹觸鏇醖膚顧) 更多
NCT00432523 (V205C-011, Pubmed \| BMC Med)	临床3期	腮腺炎 \| 麻疹 \| 水痘	-	M-M-RvaxPro intramuscular	範獵遞窪鏇製簾襯壓鏇(淵膚觸膚襯簾夢襯廠廠) = 願鑰鏇鑰網廠衊鬱築艱獵網願鬱築築憲選夢餘 (艱願選鹹鬱憲願醖願蓋 )	-	2009-04-14
AAAAI2006	N/A	蛋类过敏	78	MMR Vaccine	衊製艱醖糧夢網鹹繭餘(觸選築獵鏇製簾網鏇構) = 糧夢餘築築網襯齋簾齋艱衊衊顧鏇觸觸觸齋餘 (選顧鹽夢網鹽顧衊襯窪 )	不佳	2006-02-01
				MMR Vaccine	衊製艱醖糧夢網鹹繭餘(觸選築獵鏇製簾網鏇構) = 餘淵選構齋選醖鬱壓窪艱衊衊顧鏇觸觸觸齋餘 (選顧鹽夢網鹽顧衊襯窪 )